Back
Insulet Corporation (PODD)
Health CarePODD · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$158.29
+0.53%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$3.44
ROE
23.0%
Gross margin
71.0%
Debt/Equity
0.78x
Revenue growth
33.9%
Insulet Corporation — company intelligence
Earnings surprises
Q1 2026$1.42 vs $1.22 est+16.2%
Q4 2025$1.55 vs $1.48 est+4.5%
Q3 2025$1.24 vs $1.16 est+6.5%
Q2 2025$1.17 vs $0.95 est+23.7%
Insider activity · 90 days
10 buys2 sellsnet +17,691 shares
BORIO LUCIANASell 418 · Jun 3, 2026
STONESIFER TIMOTHY C.Buy 2,790 · Jun 3, 2026
WEATHERMAN ELIZABETH HBuy 3,450 · Jun 3, 2026
Recent SEC filings
4 — Insider transaction reportJul 2, 2026
4 — Insider transaction reportJul 2, 2026
8-K — Material event reportJun 25, 2026
Latest news
Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut? — Yahoo · 2d ago
Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain — Yahoo · 2d ago
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now? — Yahoo · 3d ago
Why Insulet (PODD) Could Beat Earnings Estimates Again — Yahoo · 3d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Insulet Corporation
Weekly undervalued picks (like PODD)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.